Cargando…
Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark(®)) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens
We report here the results of the analytical validation of assays that measure HER2 total protein (H2T) and HER2 homodimer (H2D) expression in Formalin Fixed Paraffin Embedded (FFPE) breast cancer tumors as well as cell line controls. The assays are based on the VeraTag technology platform and are c...
Autores principales: | Larson, Jeffrey S., Goodman, Laurie J., Tan, Yuping, Defazio-Eli, Lisa, Paquet, Agnes C., Cook, Jennifer W., Rivera, Amber, Frankson, Kristi, Bose, Jolly, Chen, Lili, Cheung, Judy, Shi, Yining, Irwin, Sarah, Kiss, Linda D. B., Huang, Weidong, Utter, Shannon, Sherwood, Thomas, Bates, Michael, Weidler, Jodi, Parry, Gordon, Winslow, John, Petropoulos, Christos J., Whitcomb, Jeannette M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990097/ https://www.ncbi.nlm.nih.gov/pubmed/21151530 http://dx.doi.org/10.4061/2010/814176 |
Ejemplares similares
-
HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013) -
Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer
por: Toi, Masakazu, et al.
Publicado: (2010) -
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action
por: DeFazio-Eli, Lisa, et al.
Publicado: (2011) -
Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012) -
Trastuzumab Blocks the Receiver Function of HER2 Leading to the Population Shifts of HER2-Containing Homodimers and Heterodimers
por: Zhao, Jun, et al.
Publicado: (2021)